<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">OJPed</journal-id><journal-title-group><journal-title>Open Journal of Pediatrics</journal-title></journal-title-group><issn pub-type="epub">2160-8741</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ojped.2023.136095</article-id><article-id pub-id-type="publisher-id">OJPed-128961</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Descriptive and Analytical Study of Factors Associated with Mortality in Severe Malaria among Children in Dakar Emergency Departments from July to December 2022
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Aliou</surname><given-names>Thiongane</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Abou</surname><given-names>Ba</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Fatou</surname><given-names>Ly</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Aliou</surname><given-names>A. Ndongo</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Djibril</surname><given-names>Boiro</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Younoussa</surname><given-names>Kéita</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Idrissa</surname><given-names>Basse</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Babacar</surname><given-names>Niang</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Indou</surname><given-names>Dême Ly</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Yaye</surname><given-names>Joor Dieng</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Djenaba</surname><given-names>Fafa Cissé</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ndiogou</surname><given-names>Seck</given-names></name><xref ref-type="aff" rid="aff6"><sup>6</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Lamine</surname><given-names>Thiam</given-names></name><xref ref-type="aff" rid="aff7"><sup>7</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Papa</surname><given-names>Moctar Faye</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Amadou</surname><given-names>Lamine Fall</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Assane</surname><given-names>Sylla</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ousmane</surname><given-names>Ndiaye</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>Centre Hospitalier National d’Enfants Albert Royer, Dakar, Sénégal</addr-line></aff><aff id="aff3"><addr-line>Service de pédiatrie H&amp;amp;#244;pital Pikine, Dakar, Sénégal</addr-line></aff><aff id="aff6"><addr-line>Service de pédiatrie H&amp;amp;#244;pital régional, Saint Louis, Sénégal</addr-line></aff><aff id="aff5"><addr-line>Centre Hospitalier National d’Enfants de Diamniadio, Dakar, Sénégal</addr-line></aff><aff id="aff2"><addr-line>Service de pédiatrie H&amp;amp;#244;pital Dalal Jamm, Dakar, Sénégal</addr-line></aff><aff id="aff7"><addr-line>Service de pédiatrie H&amp;amp;#244;pital de la paix de Ziguinchor, Ziguinchor, Sénégal</addr-line></aff><aff id="aff4"><addr-line>Service de pédiatrie H&amp;amp;#244;pital Abass Ndao, Dakar, Sénégal</addr-line></aff><pub-date pub-type="epub"><day>08</day><month>10</month><year>2023</year></pub-date><volume>13</volume><issue>06</issue><fpage>866</fpage><lpage>878</lpage><history><date date-type="received"><day>27,</day>	<month>September</month>	<year>2023</year></date><date date-type="rev-recd"><day>7,</day>	<month>November</month>	<year>2023</year>	</date><date date-type="accepted"><day>10,</day>	<month>November</month>	<year>2023</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Background: 
  Malaria is the most widespread parasitic disease and remains a public health priority worldwide. The severe form is fatal if not treated early and appropriately.<b> </b>The aim was to carry out a descriptive and analytical study of the factors associated with mortality during severe malaria in children attending emergency departments in Dakar, Senegal.
   
  <b>Methods: </b>
  This is a prospective, observational and analytical study conducted over a 6-month period (July 1 to December 31, 2022), focusing on children hospitalized for severe malaria according to WHO severity criteria.
   
  <b>Results: </b>
  A total of 403 patients were hospitalized, including 78 cases of severe malaria (19.35%). Males predominated (60.26%) (sex ratio 1.51). The average age was 6.56 years [8 months -
   
  14 years], with the [5
   
  -
   
  10 years] age group the most represented (40.26%). The average consultation time was 5.33 days (1
   
  -
   
  19 days). The main reasons for consultation were fever (70.51%), vomiting (24.35%) and convulsions (14.10%). Biological signs of severity were severe anemia (17.95%), renal failure (6.4%) and hypoglycemia (3.85%). Thrombocytopenia was noted in 52.56% of patients, including 32.05% of severe cases (&lt;100,000), and hyperleukocytosis in 61.41% of cases. Hyponatremia was noted in 39.74% of cases and hyperkalemia in 2 patients. Artesunate was the main drug used (93.59% of cases). Mortality was estimated at 1.5%. Factors leading to death were coma (P &lt; 0.01), respiratory distress (P &lt; 0.01) and renal failure (P &lt; 0.01). <b>Conclusion: </b>Malaria is still a public health problem, with a high mortality rate in emergency departments. Reducing this mortality rate requires effective management of the factors associated with death.
 
</p></abstract><kwd-group><kwd>Children</kwd><kwd> Malaria</kwd><kwd> Death</kwd><kwd> Factors</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Malaria is a febrile erythrocytopathy caused by a haematozoan parasite of the genus Plasmodium. It is transmitted by the infecting bite of a mosquito called the female Anopheles. There are two forms of malaria: uncomplicated malaria, which generally progresses well under treatment, and severe malaria, which is fatal if not treated early and appropriately [<xref ref-type="bibr" rid="scirp.128961-ref1">1</xref>] . Malaria is a public health priority. It is the most widespread transmissible infectious disease in the world. It is responsible for very high morbidity and mortality, especially in low- and middle-income countries, notably in Sub-Saharan Africa, South-East Asia and South America. According to the WHO 2022 malaria report, the number of cases worldwide rose between 2020 and 2021. It was estimated at 247 million in 2021, compared with 245 million in 2020. The number of deaths rose from 625,000 in 2020 to 619,000 in 2021 [<xref ref-type="bibr" rid="scirp.128961-ref2">2</xref>] . The WHO African Region continues to bear a large and disproportionate share of the global burden of this disease. In 2021, 95% of malaria cases and 96% of malaria deaths were recorded in this Region. Children under 5 accounted for 80% of all deaths due to the disease. In Senegal, the year 2021 saw a rise in malaria cases in the country, from 445,313 cases in 2020 to 536,850 in 2021 [<xref ref-type="bibr" rid="scirp.128961-ref3">3</xref>] . Malaria is one of the leading causes of death in children. The severe form is fatal if not treated early and appropriately. Several factors are thought to be associated with these deaths, including bacterial superinfection, severe and poorly tolerated anemia, hypoglycemia, respiratory distress and coma. Since 2015, the national malaria control program has recommended the use of artesunate as a first-line molecule in the etiological treatment of malaria, in line with WHO recommendations. This study will assess the impact of artesunate treatment on mortality, as well as changes in factors associated with death, in comparison with previous studies, in a context of improving the quality of emergency care. In this context that we conducted this descriptive and analytical study over a 6-month period from July 1 to December 31, 2022, in the emergency department of the Centre Hospitalier National d’Enfants Albert Royer, the main pediatric referral facility for severe forms of malaria in Dakar.</p></sec><sec id="s2"><title>2. Methods</title><sec id="s2_1"><title>2.1. Type and Duration of Study</title><p>This is a descriptive and analytical study of severe malaria cases in children admitted to paediatric emergency departments. The duration of the study was 6 months, from July 1 to December 31, 2022.</p></sec><sec id="s2_2"><title>2.2. Study Population</title><p>This study involved children hospitalized for severe malaria in the emergency department of the Centre National Hospitalier d’Enfants Albert Royer in Dakar.</p><sec id="s2_2_1"><title>2.2.1. Inclusion Criteria</title><p>All children hospitalized in emergency departments during the study period for severe malaria with:</p><p>- Rapid Diagnostic Test (RDT) or microscopy positive</p><p>- Age between 3 months and 15 years</p><p>- Presence of one or more of the WHO clinical or biological severity criteria.</p></sec><sec id="s2_2_2"><title>2.2.2. Non-Inclusion Criteria</title><p>- Outpatients</p><p>- Patients with uncomplicated malaria</p></sec></sec><sec id="s2_3"><title>2.3. Data Collection and Analysis</title><sec id="s2_3_1"><title>2.3.1. Collecting Clinical Data</title><p>Data were collected on pre-established collection forms, based on the patient’s history and clinical examination at the bedside.</p></sec><sec id="s2_3_2"><title>2.3.2. Epidemiological Data</title><p>- Patient gender</p><p>- Patient age, classified into 4 age groups: 2 - 24 months, 24 - 60 months, 60 - 120 months et superior 120 months</p><p>- Geographical origin</p><p>- Parents’ socio-economic level</p><p>- Mode of admission: referral or not</p><p>- The consultation delay, corresponding to the number of days between the onset of symptoms and the patient’s admission to the department</p><p>- Consultation reasons</p></sec><sec id="s2_3_3"><title>2.3.3. Clinical and Paraclinical Data</title><p>- Various severe forms</p><p>- Biological signs: blood count, renal and hepatic function, blood ionogram</p></sec><sec id="s2_3_4"><title>2.3.4. Therapeutic and Evolutionary Data</title><p>- Curative treatment: artesunate, artemether, ACT</p><p>- Adjuvant and symptomatic treatment: oxygen therapy, anticonvulsants, antipyretics, transfusion, antibiotics</p><p>- Mortality</p></sec><sec id="s2_3_5"><title>2.3.5. Analytical Study of Factors Associated to Death</title><p>Data were entered using Excel 2010. Analysis was performed with the following software: Excel 2010 and Epi info 7.2. For descriptive analysis, categorical variables were described using frequency tables and bar charts.</p><p>We performed a multivariate analysis on certain parameters to assess the risk of death in relation to these factors.</p><p>Quantitative variables were described by a histogram and their position (mean, median and mode) and dispersion (standard deviation, extremes) parameters.</p><p>Bivariate analysis enabled us to search for associations between variables, using the appropriate statistical tests according to their applicability conditions. The alpha risk of error was set at 5% and the CI at 95%.</p><p>The variables analyzed were:</p><p>- Age and death</p><p>- Disturbed consciousness and death</p><p>- Respiratory distress and death</p><p>- Renal failure and death</p><p>- Biological signs and death</p></sec><sec id="s2_3_6"><title>2.3.6. Ethical Concerns</title><p>All ethical rules have been respected. Informed consent was obtained from the parent or carer prior to inclusion for patients meeting the inclusion criteria.</p></sec></sec></sec><sec id="s3"><title>3. Results</title><sec id="s3_1"><title>3.1. Social and Demographic Data</title><p>During the study period, a total of 78 patients were included for severe malaria according to WHO criteria, among the 403 patients admitted to the emergency department, representing a frequency of 19.35%. The mean age of the patients was 78.72 months (8 - 168 months), with the 60 - 120 months age group predominating. Children under 60 months of age are the main target for prevention strategies in the national malaria control program, as they are less likely to develop malaria or severe malaria. Boys predominated (60.26%), with a sex ratio of 1.51. Peak visits were noted in October and November, at 29.49% and 33.33% respectively. More than half the patients came from the city center (66.67%). The socio-economic level was low to average for the vast majority (73.07%). Comorbidities were mainly sickle cell disease (6.41%) and acquired heart disease (3.85%). Fewer than half the patients were referred (35.90%). <xref ref-type="table" rid="table1">Table 1</xref> summarizes the socio-demographic characteristics for patients.</p></sec><sec id="s3_2"><title>3.2. Data from Clinical Examination</title><p>The average consultation time was 5.33 &#177; 2.8 days, with extremes of 1 and 19 days. Of our patients, 53 (67.95%) had consulted before 7 days, and 19 (24.36%)</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Distribution of patients according to socio-demographic data</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Patients’ characteristics</th><th align="center" valign="middle" >Number (n)</th><th align="center" valign="middle" >Percentage %</th></tr></thead><tr><td align="center" valign="middle" >Demographic data</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Age group (months)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Average: 78.72 (8 - 168 months)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" >[6 - 24]</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >7.69</td></tr><tr><td align="center" valign="middle" >[24 - 60]</td><td align="center" valign="middle" >21</td><td align="center" valign="middle" >27.27</td></tr><tr><td align="center" valign="middle" >[60 - 120]</td><td align="center" valign="middle" >31</td><td align="center" valign="middle" >40.26</td></tr><tr><td align="center" valign="middle" >&gt;ou = 120</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >25.97</td></tr><tr><td align="center" valign="middle" >Gender</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Boys</td><td align="center" valign="middle" >47</td><td align="center" valign="middle" >60.26</td></tr><tr><td align="center" valign="middle" >Girls</td><td align="center" valign="middle" >31</td><td align="center" valign="middle" >39.74</td></tr><tr><td align="center" valign="middle" >Geographic origin</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >City center</td><td align="center" valign="middle" >52</td><td align="center" valign="middle" >66.67</td></tr><tr><td align="center" valign="middle" >Periphery and others</td><td align="center" valign="middle" >26</td><td align="center" valign="middle" >33.33</td></tr><tr><td align="center" valign="middle" >Socio-economic status</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Low</td><td align="center" valign="middle" >26</td><td align="center" valign="middle" >33.33</td></tr><tr><td align="center" valign="middle" >Medium</td><td align="center" valign="middle" >31</td><td align="center" valign="middle" >39.74</td></tr><tr><td align="center" valign="middle" >Higher</td><td align="center" valign="middle" >21</td><td align="center" valign="middle" >26.92</td></tr><tr><td align="center" valign="middle" >Co-morbidities</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Sickle-cell disease</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >6.41</td></tr><tr><td align="center" valign="middle" >Acquired heart diseases</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >3.85</td></tr><tr><td align="center" valign="middle" >Asthma</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >2.56</td></tr><tr><td align="center" valign="middle" >Malnutrition</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.30</td></tr><tr><td align="center" valign="middle" >Cerebral Palsy</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.30</td></tr><tr><td align="center" valign="middle" >Treatment received before admission</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Herbal therapy</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >2.56</td></tr><tr><td align="center" valign="middle" >Oral antimalarial drug (ACT)</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >6.41</td></tr><tr><td align="center" valign="middle" >Injectable antimalarial drug (art&#233;sunate)</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >3.85</td></tr><tr><td align="center" valign="middle" >Antibiotics</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >12.82</td></tr><tr><td align="center" valign="middle" >Self-medication</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >8.97</td></tr><tr><td align="center" valign="middle" >Admission by referral</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >28</td><td align="center" valign="middle" >35.90</td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >50</td><td align="center" valign="middle" >64.10</td></tr><tr><td align="center" valign="middle" >Consultation period (days)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;7</td><td align="center" valign="middle" >53</td><td align="center" valign="middle" >67.95</td></tr><tr><td align="center" valign="middle" >&gt;7</td><td align="center" valign="middle" >19</td><td align="center" valign="middle" >24.36</td></tr><tr><td align="center" valign="middle" >Unspecified</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >7.69</td></tr></tbody></table></table-wrap><p>had consulted 7 days after the onset of symptoms. The reasons for consultation were dominated by fever (70.51%), vomiting (24.36%), prostration (21.79%) and neurological signs including headaches and convulsions (19.23%, 14.10%) (<xref ref-type="fig" rid="fig1">Figure 1</xref>). Fever is the symptom common to all forms of malaria, and at the same time the main warning sign of the disease. It may be moderate or very high, depending on a number of factors. In some children with nutritional disorders or immune deficiencies, it may be mild or absent. Digestive signs are also quite common in children in the context of parasitic infection, but are most common in infants in the case of primary invasion, manifesting as acute gastroenteritis. Neurological signs are mainly observed in older children, who suffer less from anemia than infants, due to the sequestration phenomena that predominate in the brain at this age. The main signs of severity on admission were prostration (41.03%), jaundice (33.33%), respiratory distress (17.95%), altered consciousness (15.38%) and seizures (10.26%) (<xref ref-type="fig" rid="fig2">Figure 2</xref>). Prostration, reflecting generalized weakness, may be symptomatic of anemia. Jaundice reflects acute hemolysis, while respiratory distress indicates pulmonary involvement in acute pulmonary edema or decompensated anemia.</p></sec><sec id="s3_3"><title>3.3. Biological Data</title><p>Biological diagnosis of malaria was based on RDT and microscopy. The RDT was positive in 87.18% of patients, negative in 3 and indeterminate in 7. Microscopy, considered by the WHO as the reference examination, was positive in all patients (100%), with a parasite density greater than 1000 parasites per microliter of blood in 42.31% of patients. CRP was positive (&gt;25 mg/l) in the majority of cases (71.80%). The haemogram showed malarial anaemia (&lt;5 g/dl) in 17.95% of patients, thrombocytopenia (&lt;150,000 platelets/mm<sup>3</sup>) in 52.56%, including</p><p>32.05% with severe forms (&lt;100,000 platelets/mm<sup>3</sup>), and hyperleukocytosis (&gt;16,000/mm<sup>3</sup>) in 30.76%. CSF analysis after lumbar puncture was performed and normal in 5 patients. There was one case of urinary tract infection (<xref ref-type="table" rid="table2">Table 2</xref>). Hypoglycemia (&lt;0.4 g/l) was noted in 3 patients. Urea was increased in 11.54% of patients, as was creatinine in 5. Blood ionograms showed hyponatremia in 39.74% of cases, and hypernatremia in 1 patient. Hypokalemia was noted in 8.97% of patients, and hyperkalemia in 2 (<xref ref-type="table" rid="table3">Table 3</xref>).</p></sec><sec id="s3_4"><title>3.4. Therapeutic Data</title><p>Management was both symptomatic and etiological. Etiological treatment involved injectable antimalarial drugs, notably artesunate and artemether. The majority of patients were on injectable artesunate (93.59%), while artemether was used in 5 patients (6.41%). Symptomatic treatment included blood transfusion (47.43%), oxygen therapy (17.95%) and anticonvulsants (10.26%). Antibiotics were used to treat bacterial infections (35.90%) (<xref ref-type="table" rid="table4">Table 4</xref>).</p></sec><sec id="s3_5"><title>3.5. Evolutionary Data</title><p>The majority (92.30%) had a favorable outcome. We noted a mortality rate of 1.5%. The factors significantly associated with these deaths were disorders of consciousness (P &lt; 0.01), respiratory distress (P &lt; 0.01) and renal failure (P &lt; 0.01). There was no significant association with mortality for the other clinical and biological variables analyzed. There was no significant relationship between age and the number of deaths (P = 0.40), gender (P = 1), hypoglycemia (P = 0.36) and bacterial superinfection (P = 1) (<xref ref-type="table" rid="table5">Table 5</xref>).</p></sec></sec><sec id="s4"><title>4. Comments</title><p>The aim of our study was to investigate the clinical and biological factors associated with mortality during severe childhood malaria in the emergency department of the Albert Royer National Children’s Hospital in Dakar, Senegal. Multivariate</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Distribution of patients according to biological signs</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Biological signs</th><th align="center" valign="middle" >Number (n)</th><th align="center" valign="middle" >Percentage %</th></tr></thead><tr><td align="center" valign="middle" >RDT</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Positive</td><td align="center" valign="middle" >68</td><td align="center" valign="middle" >87.18</td></tr><tr><td align="center" valign="middle" >N&#233;gative</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >3.85</td></tr><tr><td align="center" valign="middle" >Unspecified</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >8.97</td></tr><tr><td align="center" valign="middle" >Microscopy</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Positive</td><td align="center" valign="middle" >78</td><td align="center" valign="middle" >100</td></tr><tr><td align="center" valign="middle" >Negative</td><td align="center" valign="middle" >00</td><td align="center" valign="middle" >00</td></tr><tr><td align="center" valign="middle" >Parasite density (parasites/microlitre)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;1000</td><td align="center" valign="middle" >38</td><td align="center" valign="middle" >48.72</td></tr><tr><td align="center" valign="middle" >&gt;1000</td><td align="center" valign="middle" >33</td><td align="center" valign="middle" >42.31</td></tr><tr><td align="center" valign="middle" >Unspecified</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >8.97</td></tr><tr><td align="center" valign="middle" >CRP (mg/l)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;6</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >15.38</td></tr><tr><td align="center" valign="middle" >6 - 24</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >12.82</td></tr><tr><td align="center" valign="middle" >≥25</td><td align="center" valign="middle" >56</td><td align="center" valign="middle" >71.80</td></tr><tr><td align="center" valign="middle" >Hemogram</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Haemoglobin level (g/dl)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;5</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >17.95</td></tr><tr><td align="center" valign="middle" >[5 – 7]</td><td align="center" valign="middle" >22</td><td align="center" valign="middle" >28.20</td></tr><tr><td align="center" valign="middle" >[7- 10.9]</td><td align="center" valign="middle" >34</td><td align="center" valign="middle" >43.60</td></tr><tr><td align="center" valign="middle" >≥ 11</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >10.25</td></tr><tr><td align="center" valign="middle" >MCV (fl)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >≤80</td><td align="center" valign="middle" >54</td><td align="center" valign="middle" >69.23</td></tr><tr><td align="center" valign="middle" >80 - 100</td><td align="center" valign="middle" >22</td><td align="center" valign="middle" >22.21</td></tr><tr><td align="center" valign="middle" >≥100</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >2.56</td></tr><tr><td align="center" valign="middle" >White blood cells/mm<sup>3</sup></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;4000</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >3.84</td></tr><tr><td align="center" valign="middle" >[4000 - 12,000]</td><td align="center" valign="middle" >31</td><td align="center" valign="middle" >39.74</td></tr><tr><td align="center" valign="middle" >[12,000 - 16,000]</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >15.38</td></tr><tr><td align="center" valign="middle" >≥16,000</td><td align="center" valign="middle" >24</td><td align="center" valign="middle" >30.76</td></tr><tr><td align="center" valign="middle" >Platelet/mm<sup>3</sup></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;100,000</td><td align="center" valign="middle" >25</td><td align="center" valign="middle" >32.05</td></tr><tr><td align="center" valign="middle" >[100,000 - 150,000]</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >20.51</td></tr><tr><td align="center" valign="middle" >&gt;150,000</td><td align="center" valign="middle" >37</td><td align="center" valign="middle" >47.44</td></tr><tr><td align="center" valign="middle" >CSF</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Normal</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >6.41</td></tr><tr><td align="center" valign="middle" >Unspecified</td><td align="center" valign="middle" >73</td><td align="center" valign="middle" >93.60</td></tr><tr><td align="center" valign="middle" >UCBE</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Urinary infection</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.28</td></tr><tr><td align="center" valign="middle" >Unspecified</td><td align="center" valign="middle" >77</td><td align="center" valign="middle" >98.71</td></tr></tbody></table></table-wrap><p>RDT = Rapid Diagnostic Test, CRP = C-Reactive Protein, MCV = Mean Corpuscular Volume, CSF = cerebro-spinal fluid, UCBE = Urine Cyto-Bacteriological Examination.</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Distribution of patients according to metabolic signs</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Metabolic signs</th><th align="center" valign="middle" >Number (n)</th><th align="center" valign="middle" >Percentage %</th></tr></thead><tr><td align="center" valign="middle" >Blood glucose level (g/l)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >≤0.40</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >3.85</td></tr><tr><td align="center" valign="middle" >0.40 - 1.26</td><td align="center" valign="middle" >43</td><td align="center" valign="middle" >55.13</td></tr><tr><td align="center" valign="middle" >&gt;1.26</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >19.23</td></tr><tr><td align="center" valign="middle" >Unspecified</td><td align="center" valign="middle" >17</td><td align="center" valign="middle" >21.80</td></tr><tr><td align="center" valign="middle" >Urea</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >≤0.45 g/l</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >38.50</td></tr><tr><td align="center" valign="middle" >&gt;0.45 g/l</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >11.54</td></tr><tr><td align="center" valign="middle" >Unspecified</td><td align="center" valign="middle" >39</td><td align="center" valign="middle" >50.00</td></tr><tr><td align="center" valign="middle" >Creatininemia</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >≤12 mg/l</td><td align="center" valign="middle" >42</td><td align="center" valign="middle" >53.85</td></tr><tr><td align="center" valign="middle" >&gt;12 mg/l</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >6.41</td></tr><tr><td align="center" valign="middle" >Unspecified</td><td align="center" valign="middle" >31</td><td align="center" valign="middle" >39.74</td></tr><tr><td align="center" valign="middle" >Natremia</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;135</td><td align="center" valign="middle" >31</td><td align="center" valign="middle" >39.74</td></tr><tr><td align="center" valign="middle" >135 - 145</td><td align="center" valign="middle" >22</td><td align="center" valign="middle" >28.21</td></tr><tr><td align="center" valign="middle" >&gt;145</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.28</td></tr><tr><td align="center" valign="middle" >Kaliemia</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;3.5</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >8.97</td></tr><tr><td align="center" valign="middle" >3.5 - 5.3</td><td align="center" valign="middle" >45</td><td align="center" valign="middle" >57.69</td></tr><tr><td align="center" valign="middle" >&gt;5.3</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >2.56</td></tr><tr><td align="center" valign="middle" >Chloremia</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;98</td><td align="center" valign="middle" >24</td><td align="center" valign="middle" >30.77</td></tr><tr><td align="center" valign="middle" >98 - 108</td><td align="center" valign="middle" >27</td><td align="center" valign="middle" >34.62</td></tr><tr><td align="center" valign="middle" >&gt;108</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >3.85</td></tr><tr><td align="center" valign="middle" >Transaminases</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >High</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >10.25</td></tr><tr><td align="center" valign="middle" >Unspecified</td><td align="center" valign="middle" >70</td><td align="center" valign="middle" >89.75</td></tr><tr><td align="center" valign="middle" >Total Bilirubinemia</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >High</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >8.97</td></tr><tr><td align="center" valign="middle" >Unspecified</td><td align="center" valign="middle" >71</td><td align="center" valign="middle" >91.03</td></tr></tbody></table></table-wrap><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Therapeutic management</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Types of treatment</th><th align="center" valign="middle" >Number (n)</th><th align="center" valign="middle" >Percentage (%)</th></tr></thead><tr><td align="center" valign="middle" >Antimalarial drug (IV)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Artesunate</td><td align="center" valign="middle" >73</td><td align="center" valign="middle" >93.59</td></tr><tr><td align="center" valign="middle" >Artemether</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >6.41</td></tr><tr><td align="center" valign="middle" >Antibiotics</td><td align="center" valign="middle" >28</td><td align="center" valign="middle" >35.90</td></tr><tr><td align="center" valign="middle" >Blood transfusion</td><td align="center" valign="middle" >37</td><td align="center" valign="middle" >47.43</td></tr><tr><td align="center" valign="middle" >Oxygenotherapy</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >17.95</td></tr><tr><td align="center" valign="middle" >Antiepileptics</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >10.26</td></tr><tr><td align="center" valign="middle" >Others</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >10.82</td></tr></tbody></table></table-wrap><table-wrap id="table5" ><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> Clinical factors associated with death</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="3"  >Clinical variables</th><th align="center" valign="middle"  colspan="4"  >Death</th><th align="center" valign="middle" ></th><th align="center" valign="middle" ></th></tr></thead><tr><td align="center" valign="middle"  colspan="2"  >Yes</td><td align="center" valign="middle"  colspan="2"  >No</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >N</td><td align="center" valign="middle" >%</td><td align="center" valign="middle" >N</td><td align="center" valign="middle" >%</td><td align="center" valign="middle" >OR (CI 95%)</td><td align="center" valign="middle" >P value</td></tr><tr><td align="center" valign="middle" >Age (years)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.57 [0.35 - 0.92]</td><td align="center" valign="middle" >0.40</td></tr><tr><td align="center" valign="middle" >&lt;5</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >11.54</td><td align="center" valign="middle" >23</td><td align="center" valign="middle" >88.46</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >≥5</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >6.00</td><td align="center" valign="middle" >47</td><td align="center" valign="middle" >94.00</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Genders</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.38 [0.16 - 0.90]</td><td align="center" valign="middle" >1</td></tr><tr><td align="center" valign="middle" >Girls</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >6.67</td><td align="center" valign="middle" >28</td><td align="center" valign="middle" >93.33</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Boys</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >8.51</td><td align="center" valign="middle" >43</td><td align="center" valign="middle" >91.49</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >consciousness disorders</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >2.28 [1.31 - 3.96]</td><td align="center" valign="middle" >&lt;0.01</td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >100.00</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0.00</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >5.33</td><td align="center" valign="middle" >71</td><td align="center" valign="middle" >94.67</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Respiratory distress</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >2.18 [0.40 - 11.91]</td><td align="center" valign="middle" >&lt;0.01</td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >38.46</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >61.54</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.56</td><td align="center" valign="middle" >63</td><td align="center" valign="middle" >98.44</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Renal failure</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >4.5 [1.53 - 13.10]</td><td align="center" valign="middle" >&lt;0.01</td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >60.00</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >40.00</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >4.17</td><td align="center" valign="middle" >69</td><td align="center" valign="middle" >95.83</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Hypoglycemia</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.50 [0.10 - 0.95]</td><td align="center" valign="middle" >0.36</td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >33.33</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >66.67</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >6.94</td><td align="center" valign="middle" >67</td><td align="center" valign="middle" >93.05</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Bacterial superinfection</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >30.76</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >69.23</td><td align="center" valign="middle" >0.45 [0.15 - 0.80]</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >3.12</td><td align="center" valign="middle" >62</td><td align="center" valign="middle" >96.88</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1</td></tr></tbody></table></table-wrap><p>analysis showed 3 clinical factors strongly associated with death in children hospitalized for severe malaria in the emergency department. These were disorders of consciousness, respiratory distress and renal failure. There was no significant association between death and the other clinical and biological items, according to the results of the statistical analysis. Impaired consciousness (coma) was statistically associated with the risk of death in our study (OR = 2.28 95% CI [1.31 - 3.96]. This result is in line with the literature [<xref ref-type="bibr" rid="scirp.128961-ref4">4</xref>] . Coma results from sequestration of red blood cells in the cerebral circulation, with disruption of cerebral perfusion and oxygen supply [<xref ref-type="bibr" rid="scirp.128961-ref5">5</xref>] . This leads to neuronal damage, with cerebral edema and intracranial hypertension, which can result in brain stem compression and cardiorespiratory arrest. These phenomena justify the higher risk of death in children with these disorders of consciousness, as opposed to those without. In addition the risk of hypoglycemia, which make worse brain damage, and the risk of intracranial hypertension. Hypoglycemia in malaria results from 2 mechanisms: the use of quinine as an antimalarial drug induces insulin production and hypoglycemia, and the disruption of hepatic gluconeogenesis due to rheological disorders [<xref ref-type="bibr" rid="scirp.128961-ref6">6</xref>] . Other factors contributing to hypoglycemia include digestive disorders (diarrhea, vomiting, refusal to eat, anorexia) and dehydration. Respiratory distress (RD) was also identified as a factor associated with death during severe malaria in children hospitalized in emergency departments (OR = 2.18 95% CI [0.40 - 11.91]). In severe malaria, it generally results from an acute respiratory distress syndrome of lesional origin, leading to acute pulmonary edema with hypoxemia [<xref ref-type="bibr" rid="scirp.128961-ref7">7</xref>] . This picture of hypoxemic lesional edema often requires respiratory assistance, which is not always the case in our resource-constrained countries. Other factors increase the risk of death: refractory hypoxemia, in particular severe malarial anemia, and septic shock. Acute renal failure was the 3rd factor identified as associated with a risk of death among our patients in our study (OR = 4.5 95% CI [1.53 - 13.10]). Renal damage in malaria results from the phenomena of globular sequestration, but is favored by the occurrence of dehydration and hemodynamic disorders. The risk associated with renal damage is the occurrence of ionic complications such as hyponatremia and hyperkalemia. These ionic disorders can be complicated by intracranial hypertension and cardiac arrhythmia, leading to cardiorespiratory arrest and death [<xref ref-type="bibr" rid="scirp.128961-ref8">8</xref>] . These results have been reported by authors in Africa, notably Senegal, with young age (P = 0.025), coma (P = 0.007), respiratory distress (P = 0.04) or hypoglycemia (P = 0.001) as risk factors for death [<xref ref-type="bibr" rid="scirp.128961-ref7">7</xref>] . Other clinical and laboratory signs of severity were not associated with a higher risk of death, according to our results. It would be desirable to carry out a multicenter study over a longer period with a more representative sample in order to be able to draw conclusions. In our study, the most frequent signs of neurological severity were prostration, observed in 32 of our patients (41.03%). This result was similar to those reported by Senegalese authors [<xref ref-type="bibr" rid="scirp.128961-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.128961-ref10">10</xref>] . Other neurological signs were less frequent, including seizures and coma (10.26% and 7.69% respectively). Jaundice was found in 33.33% of our patients. Clinical anemia was noted in 57 patients (73.08%). The frequency of anemia in malaria can be explained by the importance of hemolysis due to high parasite density, the association with martial deficiency in Africa due to malnutrition. Circulatory collapse was found in 6.41% of our patients, a higher rate than the 1.8% reported by other authors [<xref ref-type="bibr" rid="scirp.128961-ref9">9</xref>] . Macroscopic hemoglobinuria was found in 2.56% of cases, a lower rate than that reported by some authors, 10.18% and 6.9% [<xref ref-type="bibr" rid="scirp.128961-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.128961-ref11">11</xref>] . Biologically, microscopy was the reference test for the biological diagnosis of malaria according to WHO recommendations. It was positive in all patients, with a mean parasite density of 7462 parasites per micro-liter of blood (720 - 110,000 parasites/microliter). These results are in line with the literature [<xref ref-type="bibr" rid="scirp.128961-ref12">12</xref>] . In addition to microscopy, RDT was also routinely performed on all children admitted with fever. It is less sensitive than microscopy, but is recommended as first-line treatment by Senegal’s national malaria control program [<xref ref-type="bibr" rid="scirp.128961-ref3">3</xref>] for all children admitted to emergency departments with fever. It was positive in 87.18% of children, while 10 children had a negative RDT (12.82%). These negative RDT results against a positive microscopy may suggest the occurrence of an HRP2 gene mutation, which is not yet the case in Senegal, although it has been described in some African countries [<xref ref-type="bibr" rid="scirp.128961-ref13">13</xref>] [<xref ref-type="bibr" rid="scirp.128961-ref14">14</xref>] . However, prevalence studies are needed to confirm or refute this hypothesis. Ionic disorders were observed in some children: hyponatremia (39.74%), hypernatremia (1.28%), hypokalemia (8.97%), hyperkalemia (2.56%). These ionic disorders are frequently described as complications of severe malaria [<xref ref-type="bibr" rid="scirp.128961-ref8">8</xref>] [<xref ref-type="bibr" rid="scirp.128961-ref15">15</xref>] . In terms of etiological treatment, almost all patients were treated with injectable artesunate in 93.59% of cases (73/78), while 6.41% (5 patients) were treated with artemether. As recommended by the WHO, the first-line treatment of severe malaria is based on the use of injectable artesunate [<xref ref-type="bibr" rid="scirp.128961-ref12">12</xref>] [<xref ref-type="bibr" rid="scirp.128961-ref15">15</xref>] . The majority (92.30%) had a favorable outcome. The mortality rate was 7.69% for patients admitted late, or with comorbidity or bacterial superinfection. However, our study has some limits. These include the small sample size (78 patients), the monocentric nature of the study, and the fact that the study period only covered the second half of the year (6 months). A prospective multi-center study with a more representative sample would enable us to confirm these findings through statistical analysis.</p></sec><sec id="s5"><title>5. Conclusion</title><p>Severe malaria is still fatal in our health facilities. Some factors have been identified as being associated with this mortality. A prospective multicenter study with a more representative sample will confirm these results.</p></sec><sec id="s6"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest regarding the publication of this paper.</p></sec><sec id="s7"><title>Cite this paper</title><p>Thiongane, A., Ba, A., Ly, F., Ndongo, A.A., Boiro, D., K&#233;ita, Y., Basse, I., Niang, B., Ly, I.D., Dieng, Y.J., Ciss&#233;, D.F., Seck, N., Thiam, L., Faye, P.M., Fall, A.L., Sylla, A. and Ndiaye, O. (2023) Descriptive and Analytical Study of Factors Associated with Mortality in Severe Malaria among Children in Dakar Emergency Departments from July to December 2022. Open Journal of Pediatrics, 13, 866-878. https://doi.org/10.4236/ojped.2023.136095</p></sec></body><back><ref-list><title>References</title><ref id="scirp.128961-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Asse, K.V., Plo, K.J., Yennan, J. and Yeboua, Y. (2014) Le paludisme du nourrisson agé de 1 à 6 mois: étude rétrospective de 50 cas colligés en 2013 à Bouaké (Cote d’ivoire). Journal de Pédiatrie et de Puériculture, 28, 1-6.  
https://doi.org/10.1016/j.jpp.2014.11.003</mixed-citation></ref><ref id="scirp.128961-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">WHO (2022) World Malaria Report 2022. World Health Organization, Geneva.  
https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2022</mixed-citation></ref><ref id="scirp.128961-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Programme National de Lutte contre le Paludisme au Sénégal (2021) Bulletin épidémiologique annuel 2021 du paludisme au Sénégal.</mixed-citation></ref><ref id="scirp.128961-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Cavallin, F., Pisani, L., Stancari, L., Massaquoi, V., Sharif, A., Pisani, E., et al. (2018) Risk Factors for Mortality in Children Admitted for Suspected Malaria to a Pediatric Emergency Ward in a Low-Resource Setting: A Case-Control Study. Pediatric Critical Care Medicine, 19, 479-485.  
https://doi.org/10.1097/PCC.0000000000001655</mixed-citation></ref><ref id="scirp.128961-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Abuga, K.M., Jones-Warner, W. and Hafalla, J.C.R. (2021) Immune Responses to Malaria Pre-Erythrocytic Stages: Implications for Vaccine Development. Parasite Immunology, 43, e12795. https://doi.org/10.1111/PIM.12795/v2/response1</mixed-citation></ref><ref id="scirp.128961-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Chiabi, A., Tchokoteu, P.F., Toupouri, A., et al. (2004) The Clinical Spectrum of Severe Malaria in Children in the East Provincial Hospital of Bertoua, Cameroon. Bulletin de la Societe de Pathologie Exotique, 97, 239-243.</mixed-citation></ref><ref id="scirp.128961-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Camara, B., Diagne-Gueye, N.R., Faye, P.M., Fall, A.L., Ndiaye, J.L., Ba, M., et al. (2011) Critères de gravité et facteurs pronostiques du paludisme chez l’enfant à Dakar. Médecine et Maladies Infectieuses, 41, 63-67.  
https://doi.org/10.1016/j.medmal.2010.09.001</mixed-citation></ref><ref id="scirp.128961-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Organisation mondiale de la Santé (2013) Guide pratique pour la prise en charge du paludisme grave. 3ème edition, World Health Organization.</mixed-citation></ref><ref id="scirp.128961-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Camara, B., Diouf, S., Diagne, I., Fall, L., Ba, A., Ba, M., et al. (2003) Le paludisme grave de l’enfant en milieu hospitalier sénégalais. Médecine et Maladies Infectieuses, 33, 45-48. https://doi.org/10.1016/S0399-077X(02)00014-8</mixed-citation></ref><ref id="scirp.128961-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Oussou-Nguiet, P.M., Okoko, A.R. and Ekouya Bowassa, G. (2013) Déterminants du neuropaludisme en milieu pédiatrique congolais. Revue Neurologique, 169, 510-514. https://doi.org/10.1016/j.neurol.2012.11.003</mixed-citation></ref><ref id="scirp.128961-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Imbert, P., Gerardin, P., Rogier, C., et al. (2003) Pertinences des critères OMS de paludisme grave chez l’enfant non immune à Dakar Sénégal. Société de Pathologie Exotique, 96, 156-160.</mixed-citation></ref><ref id="scirp.128961-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Baraka, V., Nhama, A., Aide, P., et al. (2023) Prescription Patterns and Compliance with World Health Organization Recommendations for the Management of Uncomplicated and Severe Malaria: A Prospective, Real-World Study in Sub-Saharan Africa. Malaria Journal, 22, Article No. 215.  
https://doi.org/10.1186/s12936-023-04650-y</mixed-citation></ref><ref id="scirp.128961-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Oreh, C., Esimone, C., Nworu, C. and Beshir, K. (2022) Prevalence of HRP2/3 Gene Deletion in Plasmodium falciparum Parasites in Abuja, Nigeria. International Journal of Infectious Diseases, 116, S125-S126. https://doi.org/10.1016/j.ijid.2021.12.297</mixed-citation></ref><ref id="scirp.128961-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Kobayashi, T., Sikalima, J., Parr, J.B., Chaponda, M., Stevenson, J.C., Thuma, P., et al. (2019) The Search for Plasmodium falciparum Histidine-Rich Protein 2/3 Deletions in Zambia and Implications for Plasmodium falciparum Histidine-Rich Protein 2-Based Rapid Diagnostic Tests. The American Journal of Tropical Medicine and Hygiene, 100, 842-845. https://doi.org/10.4269/ajtmh.18-0859</mixed-citation></ref><ref id="scirp.128961-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">WHO (2023) Guidelines for Malaria. World Health Organization, Geneva. https://www.who.int/publications/i/item/guidelines-for-malaria</mixed-citation></ref></ref-list></back></article>